Skip to content

A single center randomized controlled trial for human-derived neural stem cell in the treatment of ischemic stroke

A single center randomized controlled trial for human-derived neural stem cell in the treatment of ischemic stroke

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022741
Enrollment
Unknown
Registered
2019-04-24
Start date
2019-06-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Sponsors

Renji Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-80 years old; 2. patients with ischemic stroke 2 to 24 months before screening, and the stroke was caused by unilateral anterior and/or middle cerebral artery; 3. patients with hemiplegia (National Institutes of Health Stroke Scale, NIHSS) scores were higher than 6 and at least one limb movement disorder); 4. neurological de?cits were stable (variety of NIHSS was smaller than 2); 5. modified Rankin Scale scores of 2–4; 6. minimum infarct diameter of 1 cm on MRI; 7. informed consent signed by patient or family member; 8. can complete follow-up.

Exclusion criteria

Exclusion criteria: 1. with 2 or more stroke attacks (TIA was not included); 2. infarct diameter was more than 8 cm; 3. with acute coronary events 3 month before or after stroke; 4. mini-mental state examination (MMSE) score was smaller than 24; 5. with a history of seizure or taking antiepileptics; 6. taking cell therapy or a history of cell therapy (blood transfusion was not included); 7. gastrointestinal tract or other severe hemorrhagic diseases within one month before screening; 8. major surgical history one week before admission; 9. patients with abnormal coagulation, severe liver and kidney diseases, mental disorders. malignant tumor or history of malignant tumor, primary or secondary immunodeficiency; 10. pregnant or lactating women; 11. involved in other clinical trials within 3 months; 12. other patients can not cooperate with clinical researchers.

Design outcomes

Primary

MeasureTime frame
incidence of adverse events;NIHSS scores 1, 3, 6 months after hNSC injection;

Secondary

MeasureTime frame
modi?ed Rankin Scale scores 1, 3, 6 months after hNSC injection;Barthel index 1, 3, 6 months after hNSC injection;MMSE score 1, 3, 6 months after hNSC injection;Brain MRI 6, 12 months after hNSC injection;

Countries

China

Contacts

Public ContactGuan Yangtai

Renji Hospital, Shanghai Jiao Tong University School of Medicine

yangtaiguan@hotmail.com+86 13386271865

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026